In a significant win for consumer protection, the Federal Trade Commission has confirmed that Martin Shkreli violated his lifetime ban from the pharmaceutical industry, marking a major enforcement victory against corporate misconduct.

Shkreli was previously barred from pharma work after organizing an illegal scheme to maintain a monopoly on Daraprim, a critical drug that saw its price skyrocket under his watch. The FTC's action reaffirms that the agency is actively monitoring and enforcing restrictions on those who abuse their industry positions, sending a clear message that attempted end-runs around bans won't go unnoticed. Read the full story →

Today's takeaway: Regulatory oversight that actually sticks protects patients and reminds the industry that accountability matters.